Arcus Biosciences president sells 68,569 shares

Arcus Biosciences president Juan C. Jaen reported open-market sales of 68,569 shares of common stock on July 9–10, 2026, executed indirectly through a trust.

Rhea-AI Filing Summary

Arcus Biosciences president Juan C. Jaen reported open-market sales of 68,569 shares of common stock on July 9–10, 2026, executed indirectly through a trust. The trades, made under a Rule 10b5-1 trading plan, were at weighted-average prices around $28.61–$30.05 per share. He continues to hold substantial positions, including 378,291 shares held directly and more than 800,000 shares held indirectly via a trust.

Filing Explained

The president completed three plan-disclosed open-market sales; the filing changes the holder’s reported position, not Arcus’s issued shares.

The July 13, 2026 Form 4 reports that Arcus President Jaen Juan C. sold common stock in three open-market transactions dated July 9 and July 10, 2026.

The filing's disclosed structural effect is a change in the reporting person's holdings, not an issuance or sale of new Arcus shares by the company.

Transaction code S denotes an open-market sale. The filing says the sales were made under a Rule 10b5-1 trading plan, which is a written plan adopted in advance to execute trades on a schedule or formula.

The reported sales were 48,502 shares at a weighted average price of $30.053, 19,799 shares at $28.608, and 268 shares at $29.397; each price represents multiple transactions within a stated range.

Following the reported transactions, the table shows 842,307, 822,508, and 822,240 shares, respectively, and separately lists 378,291 shares that include the unvested portion of the reporting person's RSU grants.

The filing identifies the Rule 10b5-1 plan but does not state its adoption date, so the filing alone does not date when that plan was established.

Insider Trade Summary 10b5-1

Net Seller: 68,569 shares

Net Sell 4 txns

Insider Jaen Juan C.

Role President

Sold 68,569 shs ($2.03M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F3	19,799	$28.608	$566K
Sale	Common Stock F1, F4	268	$29.397	$8K
Sale	Common Stock F1, F2	48,502	$30.053	$1.46M
holding	Common Stock F5	--	--	--

Holdings After Transaction: Common Stock — 822,240 shares (Indirect, By Trust); Common Stock — 378,291 shares (Direct)

Footnotes (5)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
4. F4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
5. F5. Includes the unvested portion of the Reporting Person's RSU grants.

Key Figures

Total shares sold: 68,569 shares Block sale price (48,502 shares): $30.0530 per share Sale price (19,799 shares): $28.6080 per share +3 more

6 metrics

Total shares sold 68,569 shares Aggregate common shares sold indirectly via trust on 2026-07-09 and 2026-07-10

Block sale price (48,502 shares) $30.0530 per share Weighted-average price for 48,502 shares sold indirectly on 2026-07-09

Sale price (19,799 shares) $28.6080 per share Weighted-average price for 19,799 shares sold indirectly on 2026-07-10

Sale price (268 shares) $29.3970 per share Weighted-average price for 268 shares sold indirectly on 2026-07-10

Direct holdings 378,291 shares Common stock held directly as shown in holding entry dated 2026-07-09

Indirect trust holdings (example) 822,240 shares Common shares held indirectly by trust after a reported sale on 2026-07-10

Key Terms

Rule 10b5-1 trading plan, weighted average price, RSU grants

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

RSU grants financial

"Includes the unvested portion of the Reporting Person's RSU grants."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Arcus Biosciences (RCUS) shares did Juan C. Jaen sell in this filing?

Juan C. Jaen reported selling a total of 68,569 shares of Arcus Biosciences common stock. These were open-market sales executed indirectly through a trust over two days, according to the Form 4 transaction summary.

At what prices were the Arcus Biosciences (RCUS) shares sold in Juan C. Jaen’s Form 4?

The reported sales occurred at weighted-average prices of $30.0530, $29.3970, and $28.6080 per share. Footnotes state these averages cover multiple trades within specific intraday price ranges around each figure.

Were Juan C. Jaen’s Arcus Biosciences (RCUS) stock sales pre-planned under Rule 10b5-1?

Yes. A footnote states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Such plans pre-schedule trades, reducing the significance of trade timing as an indicator of sentiment.

How are Juan C. Jaen’s Arcus Biosciences (RCUS) shares held after these transactions?

The Form 4 shows 378,291 shares held directly and additional shares held indirectly via a trust, with indirect trust holdings exceeding 800,000 shares after the reported sales, plus unvested RSU grants included in those totals.

Do the Arcus Biosciences (RCUS) Form 4 footnotes disclose anything about RSUs?

Yes. One footnote explains that the reported share totals include the unvested portion of Juan C. Jaen’s RSU grants. This indicates part of his reported holdings consists of restricted stock units that have not yet fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaen Juan C.

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CALIFORNIA 94545

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		S		48,502(1)	D	$30.053(2)	842,307	I	By Trust
Common Stock	07/10/2026		S		19,799(1)	D	$28.608(3)	822,508	I	By Trust
Common Stock	07/10/2026		S		268(1)	D	$29.397(4)	822,240	I	By Trust
Common Stock								378,291(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.86 to $30.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.17 to $29.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.30 to $29.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

5. Includes the unvested portion of the Reporting Person's RSU grants.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)